Review of a novel hematopoietic cytokine, interleukin-11.
The novel stromal cell factor, IL-11, has been reported to have diverse effects on the lymphopoietic and myeloid/erythroid cells in vitro. These include expansion of T cell-dependent Ig-secreting B cells, proliferation and differentiation of megakaryocytic progenitors and of a variety of myeloid and erythroid precursor cells, and multiplication of pluripotential hematopoietic progenitors. In addition, IL-11 inhibits adipogenesis in vitro. In vivo administration of IL-11 elevated the number of circulating neutrophils and platelets and increased the number of megakaryocytes in the spleens of normal mice.
Quesniaux
V F
VF
Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
Mayer
P
P
Liehl
E
E
Turner
K
K
Goldman
S J
SJ
Fagg
B
B
D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy; D003520:Cyclophosphamide / Q000633:toxicity; D005260:Female; D005796:Genes; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D017370:Interleukin-11 / Q000235:genetics / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D008214:Lymphocytes / Q000166:cytology; D008533:Megakaryocytes / Q000187:drug effects; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology
D007155:Immunologic Factors; D017370:Interleukin-11; D011994:Recombinant Proteins; D003520:Cyclophosphamide